NNVC NanoViricides Inc.: Company Value to Revenue Ratio

Public company logo of NanoViricides Corp (NNVC)

NanoViricides, Inc. (NNVC) generates revenue based on the commercialization of its nanotherapeutic platform against HIV, herpes, and influenza. The EV/Sales multiple reflects the market value relative to revenue, where the value 0.00 characterizes this level. The company is currently testing the safety of molecules for skin treatment using unique "nanotraps" that block virions and prevent their mutation.

nanoviricides.com (NNVC): Company Value to Revenue from 11/23/2025 to 11/20/2026

NNVC (NanoViricides): analytical breakdowns and indicator data

- current quotes and average value forecast:
Fundamental company valuation:NNVC (NanoViricides Inc.)
Original product of nanoviricides.com

For NanoViricides, Inc. (NNVC), which is developing a diversified portfolio of nanopharmaceuticals against various viruses, the EV/Sales ratio serves as an indicator of the business's market value adjusted for net debt. This metric compares the total enterprise value to revenue, allowing investors to assess the asset's fundamental stability and rule out speculative overheating amid tight monetary policy.